Pingkuan Zhang

5.0k total citations · 2 hit papers
37 papers, 1.8k citations indexed

About

Pingkuan Zhang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pingkuan Zhang has authored 37 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Pingkuan Zhang's work include Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lung Cancer Research Studies (9 papers). Pingkuan Zhang is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lung Cancer Research Studies (9 papers). Pingkuan Zhang collaborates with scholars based in United States, France and South Korea. Pingkuan Zhang's co-authors include Bruce E. Johnson, Bijoyesh Mookerjee, Julien Mazières, David Planchard, Benjamin Besse, Harry J.M. Groen, Anthony M. D’Amelio, Vanessa Giannone, Egbert F. Smit and Åslaug Helland and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Pingkuan Zhang

37 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 948 citations David Planchard, Egbert F. Smit et al. The Lancet Oncology profile →
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 612 citations David Planchard, Benjamin Besse et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Pingkuan Zhang

Since Specialization

Citations

This map shows the geographic impact of Pingkuan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pingkuan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pingkuan Zhang more than expected).

Fields of papers citing papers by Pingkuan Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pingkuan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pingkuan Zhang. The network helps show where Pingkuan Zhang may publish in the future.

Co-authorship network of co-authors of Pingkuan Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Pingkuan Zhang. A scholar is included among the top collaborators of Pingkuan Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pingkuan Zhang. Pingkuan Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status 2025 ·Clinical Lung Cancer ·Lyudmila Bazhenova, John Hodgson, D. Ross Camidge, Corey J. Langer, Rudolf M. Huber, Dong-Wan Kim, Karen L. Reckamp, Myung‐Ju Ahn, Daniel Shao-Weng Tan, Jyoti D. Patel, Sylvie Vincent, Cong Li, Michael Humphries, Pingkuan Zhang, Victor M. Rivera, Scott Gettinger	1
2	Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana I. Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta	2
3	Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial 2023 ·Cancer Science ·Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Kōichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, (unknown), Pingkuan Zhang, Kazuhiko Nakagawa	7
4	Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison 2023 ·Lung Cancer ·Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal	4
5	Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations 2023 ·Lung Cancer ·Petros Christopoulos, (unknown), Jin‐Liern Hong, Huamao Mark Lin, Luis Hernández, Shu Jin, Min Tan, Irina Proskorovsky, Jianchang Lin, Pingkuan Zhang, Jyoti D. Patel, Sai‐Hong Ignatius Ou, Michael Thomas, Albrecht Stenzinger	3
6	Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor 2023 ·Clinical Pharmacokinetics ·Neeraj Gupta, Michael J. Hanley, Robert Griffin, Pingkuan Zhang, Karthik Venkatakrishnan, Vikram Sinha	7
7	Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison 2023 ·Clinical Lung Cancer ·Sai‐Hong Ignatius Ou, (unknown), Huamao Mark Lin, Jin‐Liern Hong, Min Tan, Irina Proskorovsky, Luis Hernández, Shu Jin, Pingkuan Zhang, Jianchang Lin, Jyoti D. Patel, Danny Nguyen, Joel W. Neal	3
8	Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC 2022 ·Clinical and Translational Science ·Neeraj Gupta, Karen L. Reckamp, David Ross Camidge, Huub Jan Kleijn, (unknown), Francesco Bellanti, John Maringwa, Michael J. Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan	5
9	Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study 2022 ·International Journal of Clinical Oncology ·Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Kōichi Goto, Kazuhiko Nakagawa, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, (unknown), Pingkuan Zhang, Yuichiro Ohe	5
10	Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib. 2022 ·Journal of Clinical Oncology ·Sylvie Vincent, Zhenqiang Su, Veronica Bunn, Adarsh Joshi, (unknown), Sampurna Chatterjee, Minakshi Guha, Pingkuan Zhang	2
11	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) 2021 ·Lung Cancer ·M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge	12
12	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial 2020 ·Journal of Thoracic Oncology ·Makoto Nishio, Tatsuya Yoshida, Toru Kumagai, Toyoaki Hida, Ryo Toyozawa, Tadasuke Shimokawaji, Kōichi Goto, Kazuhiko Nakagawa, Yuichiro Ohe, Takashi Seto, Kentarou Kudou, (unknown), Pingkuan Zhang, Nobuyuki Yamamoto	47
13	Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study 2020 ·CPT Pharmacometrics & Systems Pharmacology ·Neeraj Gupta, Xiaohui Wang, Elliot Offman, Benjamin E. Rich, David Kerstein, Michael J. Hanley, Paul M. Diderichsen, Pingkuan Zhang, Karthik Venkatakrishnan	14
14	Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study 2019 ·Journal of Medical Economics ·Ariane K. Kawata, William R. Lenderking, (unknown), David Kerstein, (unknown), Hui Huang, Pingkuan Zhang, Huamao Mark Lin	9
15	Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC). 2019 ·Journal of Clinical Oncology ·Rosario García Campelo, Huamao Mark Lin, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Yanyan Zhu, Pingkuan Zhang, D. Ross Camidge	4
16	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer 2018 ·Lung Cancer ·Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasané, Anand A. Dalal, (unknown), Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson	12
17	Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis 2018 ·Advances in Therapy ·Junlong Li, Medha Sasané, (unknown), (unknown), Pingkuan Zhang, (unknown), Zheng‐Yi Zhou, James Signorovitch	7
18	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial breakdown → 2017 ·The Lancet Oncology ·David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson	948
19	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial breakdown → 2016 ·The Lancet Oncology ·David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Élisabeth Quoix, Christina S. Baik, Fabrice Barlési, Tae Min Kim, Julien Mazières, Silvia Novello, James R. Rigas, Allison Upalawanna, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson	612
20	Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models 2013 ·Oncology Reports ·(unknown), Xia Qin, Xuehua Zhu, (unknown), Ping Liu, Li Liu, Hanlim Moon, Pingkuan Zhang, Joel Greshock, Kurtis E. Bachman, Bang‐Ce Ye, Hui Wang, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact